A triple combination of atorvastatin, celecoxib and tipifarnib strongly inhibits pancreatic cancer cells and xenograft pancreatic tumors

Because K-Ras mutation and cyclooxygenase-2 (COX-2) overexpression are hallmarks of majority of pancreatic cancer patients, an approach to inhibit the progression and growth of pancreatic cancer using the simultaneous administration of agents that inhibit the function of both targets, should be cons...

Descripción completa

Detalles Bibliográficos
Autores principales: DING, NING, CUI, XIAO-XING, GAO, ZHI, HUANG, HUARONG, WEI, XINGCHUAN, DU, ZHIYUN, LIN, YONG, SHIH, WEICHUNG JOE, RABSON, ARNOLD B., CONNEY, ALLAN H., HU, CHUNHONG, ZHENG, XI
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2014
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4063540/
https://www.ncbi.nlm.nih.gov/pubmed/24647860
http://dx.doi.org/10.3892/ijo.2014.2350

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4063540/
https://www.ncbi.nlm.nih.gov/pubmed/24647860
http://dx.doi.org/10.3892/ijo.2014.2350

Ejemplares similares